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ABSTRACT
Tumors defective in homologous recombination (HR) are highly sensitive to poly ADP-ribose polymerase
(PARP) inhibition, however the cell biological mechanisms underlying this synthetic lethality remain
elusive. We recently identiﬁed that PARP inhibitor-induced DNA lesions persist until mitosis, subsequently





BRCA1 and BRCA2 are essential in achieving error-free repair
of DNA double stranded breaks (DSBs) through homologous
recombination (HR). Mutations in HR genes, therefore, result
in defective genome maintenance and predispose to tumouri-
genesis, primarily in breast and ovarian tissues. The resulting
HR-defective tumors appeared highly sensitive to inhibitors of
PARP,1,2 resulting in the successful clinical development of
PARP inhibitors for patients with BRCA1/2 mutant cancers.
Unfortunately, however, patients often develop resistance to
PARP inhibitors and relapse. To identify possible new combi-
nation strategies that improve PARP inhibitor therapy, molecu-
lar insight into the mechanism of PARP inhibitor cytotoxicity
in HR-deﬁcient tumor cells is required.
Exactly how cancer cells with defective HR die following
PARP inhibition remains incompletely clear. Initially, loss of
PARP was reported to cause single stranded DNA break (SSB)
accumulation, owing to the role of PARP in base excision repair
(BER).1,2 High levels of SSBs would then, through the course of
DNA replication, lead to DSB formation, which in HR-deﬁcient
cells ultimately results in cell death. However, the role of PARP
inhibitors in BER and ensuing SSB accumulation is debated,
suggesting that other functions of PARP and HR genes are
involved in cell death induction.3 Speciﬁcally, HR components
as well as PARP were found to have important functions in the
protection and restart of replication forks.4,5
We recently showed that HR-deﬁcient cancer cells indeed have
compromised fork stability when treated with PARP inhibitors,
and accordingly present with high levels of FANCD2 foci during
replication.6 Surprisingly, these DNA lesions appear to remain
unresolved in S or G2 phase, and instead are propagated into
mitosis, resulting in chromatin bridge formation in anaphase.6 Of
note, using live cell imaging we observed that PARP inhibitor-
induced chromatin bridges led to multinucleation and cell death.
Our ﬁndings reiterate that replication lesions can be trans-
mitted into mitosis.7 Although we focused on the mitotic
transmission of PARP inhibitor-induced lesions, it is highly
likely that numerous other replication lesions can ultimately be
transmitted into mitosis, and through this phenomenon affect
cell fate (Fig. 1). In this Author’s View, we will further discuss
our ﬁndings and implications thereof.
Consequences and processing of mitotic DNA damage
Exactly how mitotic DNA damage triggers cell death is unclear.
One possibility involves differential wiring of the apoptotic
machinery during mitosis, or that apoptosis is activated at a
lower threshold following mitotic entry. Indeed, mitotic kin-
ases, notably Cyclin-dependent kinase-1 (Cdk1), were reported
to modify pro- as well as anti-apoptotic proteins, including Bcl-
XL, Bcl-2, Mcl-1 and several caspases.
8 However, multiple mito-
sis-dependent modiﬁcations of the apoptosis machinery make
cells resistant rather than susceptible to apoptosis. Additionally,
some of the reported pro-apoptotic effects during mitosis are
only instigated during prolonged mitotic spindle checkpoint
arrest, and therefore do not necessarily reﬂect the situation of
cells entering with unresolved DNA lesions.
Another possibility involves replication-mediated joint
DNA molecules being transformed into more toxic DNA
lesions, such as DSBs, during mitosis. Indeed, replication-medi-
ated DNA lesions that remain unresolved until mitotic entry
are acted upon by the MUS81/EME nuclease,7 probably as part
of a complex of multiple structure-selective nucleases.9 Process-
ing of DNA lesions does not necessarily lead to an accumula-
tion of toxic DNA structures, since nuclease-mediated
processing of mitotic DNA lesions is an initial step in their res-
olution. However, PARP inhibitor treatment in the context of
HR deﬁciency might lead to an overwhelming load of DNA
lesions, beyond the capacity of mitotic repair. Alternatively,
efﬁcient processing of mitotic DNA lesions may be hampered
in cells with inactivated HR and PARP.
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Additionally, physical tension, exerted onto chromatin
bridge DNA by spindle force, could be responsible for cell
death, either directly or through the generation of DSBs. Alter-
natively, cytokinesis failure and consequent formation of multi-
nucleated cells might constitute another way cells could
eventually generate toxic DNA lesions which lead to cell
death.10
Likely, multiple of the abovementioned mechanisms occur
in parallel to instigate cell death. A notion which is supported
by our ﬁnding that subsets of PARP inhibitor-treated cells die
prior to completing mitosis, whereas others fail to undergo
cytokinesis, leading to multinucleation and subsequent cell
death. Understanding apoptotic cues in mitosis will prove piv-
otal for exploiting this knowledge to potentiate therapeutic
strategies relying on mitotic catastrophe for anti-cancer
cytotoxicity.
The role of mitotic transmission of DNA lesions in
cancer cell fate
Mitotic catastrophe is frequently thought to be responsible, as
least partly, for cytotoxicity of current cancer treatments. Our
report, to our knowledge, for the ﬁrst time uses forced mitotic
bypass induced by depletion of Early Mitotic Inhibitor-1 (EMI1),
as a tool to assess the contribution of mitotic progression to cell
death. We implemented this tool to test the contribution of
mitotic progression to the cytotoxicity of PARP inhibitors in
HR-deﬁcient cells. However, this approach can be applied simi-
larly to test other agents. We showed that, for instance, cisplatin,
also induces mitotic chromatin bridges in a HR-deﬁcient cancer
cells.6 Additionally, oncogene-induced replication stress also
results in under-replicated lesions, and it would therefore be
interesting to see whether mitotic catastrophe is observed in
tumors with oncogene-induced replication stress. Later ﬁndings
would ﬁt a model in which mitotic catastrophe presents a possi-
ble mechanism clearing cells upon chromosome miss-
segregation, genetic instability and tumourigenesis. Since the
cytotoxicity of PARP inhibitors in HR-deﬁcient cells is promoted
by mitotic progression, it is interesting to speculate that cancer
cells harboring DNA replication lesions maintain viable by
arresting the cell cycle. Targeting of DNA damage checkpoint
kinases, including WEE1, could be used to abrogate cell cycle
arrest, push PARP inhibitor-treated cells into mitosis, and pro-
mote cell death.
In summary, a better understanding of the mitotic ‘death
cues’ that underlie the cytotoxicity of PARP inhibitors, and
possible many other anti-cancer agents, will aid in directing the
development of improved cancer treatments. Although mitotic
catastrophe in response to DNA damage induction has been
reported for decades, molecular cues that are responsible for
mitotic catastrophe remain elusive, and additional research is
warranted to uncover the mechanisms underlying this
phenomenon.
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